drugset / Trial / NCT00555061

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

NCT00555061

Phase 4 Completed 60 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Timeline

Start
2007-09
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Retapamulin Small molecule 1 % Topical